<p>根据 P2 Capital Partners LLC 最近向证券交易委员会提交的 13F 文件，该公司在 2023 年第三季度将其在阿卡迪亚医疗保健公司（NASDAQ:ACHC - 免费报告）的股份增加了 9.1%。该基金在此期间购买了额外的 195,000 股后，持有该公司 2,337,188 股股票。阿卡迪亚医疗保健占 P2 Capital Partners LLC 持有的股份的 11.1%，使其成为该基金第三大持股。P2 Capital Partners LLC 在最近一个季度末持有的阿卡迪亚医疗保健股份约占 2.53%，价值 57,869,000 美元。</p>
<p>获取 <strong>Acadia Healthcare</strong> 的提醒：</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
<p>其他几家大型投资者也调整了对该公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度购买了阿卡迪亚医疗保健的新股份，价值约为 1,600,000 美元。高盛集团在第一季度将其在阿卡迪亚医疗保健的持股增加了 21.1%。高盛集团目前持有 698,225 股该公司的股票，价值 21,170,000 美元，此前在上个季度又收购了 121,444 股。瑞银资产管理公司旗下的一个独立业务单位在第一季度将其在阿卡迪亚医疗保健的股份增加了 8.7%。瑞银资产管理公司目前持有 340,916 股该公司的股票，价值 10,337,000 美元，此前在此期间又购买了 27,207 股。Envestnet 资产管理公司在第二季度将其在阿卡迪亚医疗保健的股份增加了 54.2%。Envestnet 资产管理公司目前持有 166,880 股该公司的股票，价值 3,786,000 美元，此前在上个季度又购买了 58,642 股。最后，Allworth Financial LP 在第二季度将其在阿卡迪亚医疗保健的股份增加了 676.4%。Allworth Financial LP 目前持有 1,351 股该公司的股票，价值 31,000 美元，此前在此期间又购买了 1,177 股。</p>
<h2>阿卡迪亚医疗保健的关键新闻</h2>
<p>以下是本周影响阿卡迪亚医疗保健的关键新闻：</p>
<ul>
<li>积极情绪：阿卡迪亚将 Daniel Cancelmi 加入其董事会，这一治理举措被视为扩大董事会专业知识和监督的积极信号。文章标题</li>
<li>中性情绪：报告的空头头寸数据显示零股数和 0.0 的覆盖天数——该发布似乎包含异常或缺失数据（NaN/0），因此未能提供关于看跌头寸的明确信号。</li>
<li>消极情绪：Zacks Research 下调了多个短期和多年期的每股收益（EPS）预期，并维持 “持有” 评级。关键变化包括将 2026 年第二季度的 EPS 下调至 0.49 美元（从 0.66 美元），2026 财年的 EPS 下调至 1.48 美元（从 1.85 美元），2027 财年的 EPS 下调至 1.55 美元（从 1.96 美元），以及在 2026 年至 2027 年间的多个季度逐步下调。这些下调降低了投资者的预期，是今天股价下跌的主要原因。</li>
</ul>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该股票发表了评论。Guggenheim 将阿卡迪亚医疗保健的目标股价从 27.00 美元下调至 22.00 美元，并在 2 月 23 日的研究报告中对该股票给予 “买入” 评级。瑞银集团将阿卡迪亚医疗保健的目标股价从 24.00 美元上调至 27.00 美元，并在 2 月 26 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 1 月 21 日的研究报告中重申了对阿卡迪亚医疗保健的 “卖出（d）” 评级。KeyCorp 在 12 月 3 日的报告中将阿卡迪亚医疗保健的目标股价从 30.00 美元下调至 25.00 美元，并对该公司给予 “超配” 评级。最后，美国银行在 12 月 3 日的研究报告中将阿卡迪亚医疗保健的评级从 “中性” 下调至 “表现不佳”，并将该股票的目标价从 21.50 美元下调至 13.00 美元。七位研究分析师对该股票给予 “买入” 评级，七位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 21.15 美元。</p>
<p><strong>查看我们对 ACHC 的最新分析</strong></p>
<h2>阿卡迪亚医疗保健股价下跌 2.6%</h2>
<p>NASDAQ:ACHC 周五开盘价为 23.52 美元。该公司的 50 日简单移动平均线为 16.80 美元，200 日简单移动平均线为 18.78 美元。阿卡迪亚医疗保健公司一年的最低价为 11.43 美元，最高价为 31.04 美元。该公司的市值为 21.7 亿美元，市盈率为-1.93，市盈率/增长比率为 8.16，贝塔值为 0.74。该公司的债务与股本比率为 1.27，速动比率为 1.55，流动比率为 1.55。</p>
<p>阿卡迪亚医疗保健（NASDAQ:ACHC - 获取免费报告）最后一次发布季度财报是在 2 月 25 日。该公司报告本季度每股收益（EPS）为 0.07 美元，超出分析师一致预期的 0.03 美元，超出幅度为 0.04 美元。该公司本季度的收入为 8.2146 亿美元，而一致预期为 8.001 亿美元。阿卡迪亚医疗保健的净利润率为-33.29%，股本回报率为 6.53%。该公司的季度收入同比增长 6.1%。去年同期，该公司每股收益为 0.64 美元。阿卡迪亚医疗保健已将其 2026 财年的指导目标设定为 1.300-1.550 EPS，并将其 2026 年第一季度的指导目标设定为 0.250-0.300 EPS。股票分析师预计阿卡迪亚医疗保健公司将在本财年发布 3.38 EPS。</p>
<h2>关于阿卡迪亚医疗保健</h2>
<p>（免费报告）</p>
<p>阿卡迪亚医疗保健公司（NASDAQ: ACHC）是一家公开交易的行为健康服务提供商，总部位于田纳西州富兰克林。该公司成立于 2005 年，通过有机扩张和战略收购不断发展，已成为美国心理健康和成瘾治疗领域的领先专家。</p>
<p>阿卡迪亚运营着一个多元化的住院精神病医院、住院治疗中心、门诊诊所和强化门诊项目的网络。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比阿卡迪亚医疗保健更好的股票</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：今天就来认领你的股份</li>
<li>伊朗并不是真正的战争</li>
<li>在 Starlink 上市前购买的 30 美元股票（立即观看！）</li>
<li>这枚硬币具备一切优势</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNIQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNIQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿卡迪亚医疗保健吗？</h2>
<p>在考虑阿卡迪亚医疗保健之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿卡迪亚医疗保健并不在名单上。</p>
<p>虽然阿卡迪亚医疗保健目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿卡迪亚医疗保健

<p>P2 Capital Partners LLC 在第三季度将其在阿卡迪亚医疗保健公司（NASDAQ: ACHC）的持股增加了 9.1%，目前持有 2,337,188 股，使其成为该基金的第三大头寸。其他投资者，包括高盛和瑞银，也增加了他们的持股。然而，Zacks Research 下调了每股收益的预期，导致该股票承压，目前交易价格为 23.52 美元，下跌 2.6%。分析师评级不一，平均评级为 “持有”，目标价格为 21.15 美元</p>

<p>P2 Capital Partners LLC boosted its position in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) by 9.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,337,188 shares of the company's stock after purchasing an additional 195,000 shares during the period. Acadia Healthcare comprises 11.1% of P2 Capital Partners LLC's holdings, making the stock its 3rd biggest holding. P2 Capital Partners LLC owned approximately 2.53% of Acadia Healthcare worth $57,869,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 P2 Capital Partners LLC 最近向证券交易委员会提交的 13F 文件，该公司在 2023 年第三季度将其在阿卡迪亚医疗保健公司（NASDAQ:ACHC - 免费报告）的股份增加了 9.1%。该基金在此期间购买了额外的 195,000 股后，持有该公司 2,337,188 股股票。阿卡迪亚医疗保健占 P2 Capital Partners LLC 持有的股份的 11.1%，使其成为该基金第三大持股。P2 Capital Partners LLC 在最近一个季度末持有的阿卡迪亚医疗保健股份约占 2.53%，价值 57,869,000 美元。</p>
</div><p>Get <strong>Acadia Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Acadia Healthcare</strong> 的提醒：</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
</div><p>Several other large investors have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Acadia Healthcare in the first quarter worth approximately $1,600,000. Goldman Sachs Group Inc. grew its position in Acadia Healthcare by 21.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company's stock valued at $21,170,000 after acquiring an additional 121,444 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Acadia Healthcare by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company's stock worth $10,337,000 after purchasing an additional 27,207 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Acadia Healthcare by 54.2% during the second quarter. Envestnet Asset Management Inc. now owns 166,880 shares of the company's stock worth $3,786,000 after purchasing an additional 58,642 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Acadia Healthcare by 676.4% during the second quarter. Allworth Financial LP now owns 1,351 shares of the company's stock valued at $31,000 after purchasing an additional 1,177 shares during the period.</p>
<div class="lb-trans"><p>其他几家大型投资者也调整了对该公司的持股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度购买了阿卡迪亚医疗保健的新股份，价值约为 1,600,000 美元。高盛集团在第一季度将其在阿卡迪亚医疗保健的持股增加了 21.1%。高盛集团目前持有 698,225 股该公司的股票，价值 21,170,000 美元，此前在上个季度又收购了 121,444 股。瑞银资产管理公司旗下的一个独立业务单位在第一季度将其在阿卡迪亚医疗保健的股份增加了 8.7%。瑞银资产管理公司目前持有 340,916 股该公司的股票，价值 10,337,000 美元，此前在此期间又购买了 27,207 股。Envestnet 资产管理公司在第二季度将其在阿卡迪亚医疗保健的股份增加了 54.2%。Envestnet 资产管理公司目前持有 166,880 股该公司的股票，价值 3,786,000 美元，此前在上个季度又购买了 58,642 股。最后，Allworth Financial LP 在第二季度将其在阿卡迪亚医疗保健的股份增加了 676.4%。Allworth Financial LP 目前持有 1,351 股该公司的股票，价值 31,000 美元，此前在此期间又购买了 1,177 股。</p>
</div><h2>Key Acadia Healthcare News</h2>
<div class="lb-trans"><h2>阿卡迪亚医疗保健的关键新闻</h2>
</div><p>Here are the key news stories impacting Acadia Healthcare this week:</p>
<div class="lb-trans"><p>以下是本周影响阿卡迪亚医疗保健的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Acadia added Daniel Cancelmi to its Board of Directors, a governance move that can be viewed positively as expanding board expertise and oversight. Article Title</li>
<li>Neutral Sentiment: Reported short-interest data shows zero shares and days-to-cover of 0.0 — the release appears to contain anomalous or missing data (NaN/0) and therefore provides no clear signal about bearish positioning.</li>
<li>Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and keeps a &#34;Hold&#34; rating. Key changes include Q2 2026 EPS cut to $0.49 (from $0.66), FY2026 to $1.48 (from $1.85), and FY2027 to $1.55 (from $1.96), plus several quarter-by-quarter reductions across 2026–2027. These downward revisions lower investor expectations and are the main reason for today’s downward pressure on the stock.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：阿卡迪亚将 Daniel Cancelmi 加入其董事会，这一治理举措被视为扩大董事会专业知识和监督的积极信号。文章标题</li>
<li>中性情绪：报告的空头头寸数据显示零股数和 0.0 的覆盖天数——该发布似乎包含异常或缺失数据（NaN/0），因此未能提供关于看跌头寸的明确信号。</li>
<li>消极情绪：Zacks Research 下调了多个短期和多年期的每股收益（EPS）预期，并维持 “持有” 评级。关键变化包括将 2026 年第二季度的 EPS 下调至 0.49 美元（从 0.66 美元），2026 财年的 EPS 下调至 1.48 美元（从 1.85 美元），2027 财年的 EPS 下调至 1.55 美元（从 1.96 美元），以及在 2026 年至 2027 年间的多个季度逐步下调。这些下调降低了投资者的预期，是今天股价下跌的主要原因。</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts recently commented on the stock. Guggenheim reduced their price target on shares of Acadia Healthcare from $27.00 to $22.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, February 23rd. UBS Group upped their target price on shares of Acadia Healthcare from $24.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Acadia Healthcare in a research note on Wednesday, January 21st. KeyCorp lowered their price target on Acadia Healthcare from $30.00 to $25.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, December 3rd. Finally, Bank of America cut Acadia Healthcare from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and dropped their price objective for the stock from $21.50 to $13.00 in a research note on Wednesday, December 3rd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $21.15.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发表了评论。Guggenheim 将阿卡迪亚医疗保健的目标股价从 27.00 美元下调至 22.00 美元，并在 2 月 23 日的研究报告中对该股票给予 “买入” 评级。瑞银集团将阿卡迪亚医疗保健的目标股价从 24.00 美元上调至 27.00 美元，并在 2 月 26 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 1 月 21 日的研究报告中重申了对阿卡迪亚医疗保健的 “卖出（d）” 评级。KeyCorp 在 12 月 3 日的报告中将阿卡迪亚医疗保健的目标股价从 30.00 美元下调至 25.00 美元，并对该公司给予 “超配” 评级。最后，美国银行在 12 月 3 日的研究报告中将阿卡迪亚医疗保健的评级从 “中性” 下调至 “表现不佳”，并将该股票的目标价从 21.50 美元下调至 13.00 美元。七位研究分析师对该股票给予 “买入” 评级，七位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 21.15 美元。</p>
</div><p><strong>View Our Latest Analysis on ACHC</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ACHC 的最新分析</strong></p>
</div><h2>Acadia Healthcare Trading Down 2.6%</h2>
<div class="lb-trans"><h2>阿卡迪亚医疗保健股价下跌 2.6%</h2>
</div><p>NASDAQ:ACHC opened at $23.52 on Friday. The firm has a 50-day simple moving average of $16.80 and a 200-day simple moving average of $18.78. Acadia Healthcare Company, Inc. has a one year low of $11.43 and a one year high of $31.04. The firm has a market cap of $2.17 billion, a P/E ratio of -1.93, a P/E/G ratio of 8.16 and a beta of 0.74. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55.</p>
<div class="lb-trans"><p>NASDAQ:ACHC 周五开盘价为 23.52 美元。该公司的 50 日简单移动平均线为 16.80 美元，200 日简单移动平均线为 18.78 美元。阿卡迪亚医疗保健公司一年的最低价为 11.43 美元，最高价为 31.04 美元。该公司的市值为 21.7 亿美元，市盈率为-1.93，市盈率/增长比率为 8.16，贝塔值为 0.74。该公司的债务与股本比率为 1.27，速动比率为 1.55，流动比率为 1.55。</p>
</div><p>Acadia Healthcare (NASDAQ:ACHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.04. The firm had revenue of $821.46 million for the quarter, compared to the consensus estimate of $800.10 million. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The company's quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the firm earned $0.64 earnings per share. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. Equities analysts anticipate that Acadia Healthcare Company, Inc. will post 3.38 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿卡迪亚医疗保健（NASDAQ:ACHC - 获取免费报告）最后一次发布季度财报是在 2 月 25 日。该公司报告本季度每股收益（EPS）为 0.07 美元，超出分析师一致预期的 0.03 美元，超出幅度为 0.04 美元。该公司本季度的收入为 8.2146 亿美元，而一致预期为 8.001 亿美元。阿卡迪亚医疗保健的净利润率为-33.29%，股本回报率为 6.53%。该公司的季度收入同比增长 6.1%。去年同期，该公司每股收益为 0.64 美元。阿卡迪亚医疗保健已将其 2026 财年的指导目标设定为 1.300-1.550 EPS，并将其 2026 年第一季度的指导目标设定为 0.250-0.300 EPS。股票分析师预计阿卡迪亚医疗保健公司将在本财年发布 3.38 EPS。</p>
</div><h2>About Acadia Healthcare</h2>
<div class="lb-trans"><h2>关于阿卡迪亚医疗保健</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Acadia Healthcare Company, Inc NASDAQ: ACHC is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.</p>
<div class="lb-trans"><p>阿卡迪亚医疗保健公司（NASDAQ: ACHC）是一家公开交易的行为健康服务提供商，总部位于田纳西州富兰克林。该公司成立于 2005 年，通过有机扩张和战略收购不断发展，已成为美国心理健康和成瘾治疗领域的领先专家。</p>
</div><p>Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.</p>
<div class="lb-trans"><p>阿卡迪亚运营着一个多元化的住院精神病医院、住院治疗中心、门诊诊所和强化门诊项目的网络。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Acadia Healthcare</li>
<li>A personal warning from Martin Weiss (Please read)</li>
<li>SpaceX IPO Confirmed: Claim Your Stake Today</li>
<li>Iran isn't the real war</li>
<li>$30 stock to buy before Starlink goes public (WATCH NOW!)</li>
<li>This coin has everything going for it</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比阿卡迪亚医疗保健更好的股票</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：今天就来认领你的股份</li>
<li>伊朗并不是真正的战争</li>
<li>在 Starlink 上市前购买的 30 美元股票（立即观看！）</li>
<li>这枚硬币具备一切优势</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNIQw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ACHC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acadia Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿卡迪亚医疗保健吗？</h2>
</div><p>Before you consider Acadia Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿卡迪亚医疗保健之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acadia Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿卡迪亚医疗保健并不在名单上。</p>
</div><p>While Acadia Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿卡迪亚医疗保健目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿卡迪亚医疗保健公司 $ACHC 是 P2 Capital Partners LLC 的第三大持仓